Mangafodipyr (sold under the brand name Teslascan in the form of mangafodipir trisodium) is an intravenous contrast agent to improve contrast during magnetic resonance imaging (MRI) of the liver .
| Mangafodipyr | |
|---|---|
 | |
 | |
| Chemical compound | |
| Gross formula | C 22 H 32 MnN 4 O 14 P 2 + 2 |
| Molar mass | 689.362 g / mol |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| ATX | |
| Pharmacokinetics | |
| Bioavailable | NA |
| Plasma Protein Binding | 27% (manganese) Minor (DPDP) |
| The half-life. | 20 minutes (manganese) 50 minutes (DPDP) |
| Excretion | Renal and fecal (manganese) Renal (DPDP) |
| Route of administration | |
| Intravenous infusion | |
It consists of two parts - paramagnetic manganese (II) ions and chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Normal liver tissues absorb manganese in large quantities compared to abnormal or cancerous ones. Manganese can reduce the longitudinal relaxation time (T 1 ), making normal tissue brighter for MRI. This allows you to increase the contrast of the affected areas and better identify them.
The compound was protected by US patent [1] , the term of protection of which, according to the Drug Patent Expiration Bulletin [2], expired on November 27, 2011 .
Links
Notes
- ↑ US Patent No. 4,933,456 of June 12, 1990. Dipyridoxyl phosphate NMRI contrast agents . Description of the patent on the website of the US Patent and Trademark Office .
- ↑ Search for Tradename: TESLASCAN